289 results on '"Grohe C"'
Search Results
2. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
3. Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study
4. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer
5. Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.
6. MA16.11 Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC
7. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
8. Atherosclerotic Vessel Changes in Sarcoidosis
9. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial
10. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer
11. LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study
12. OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results
13. P3.13C.09 First-Line Treatments for Advanced Pure Large Cell Neuroendocrine Tumors (LCNEC):Insights from a Global Clinico-Genomic Study.
14. 296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
15. LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA
16. PET and PET/CT with F-18 Fluoride in Bone Metastases
17. EP08.01-021 Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy
18. P1.15-05 Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)
19. LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
20. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
21. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
22. BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort
23. Pulmonales Onkozytom mit simultanem Schwannom – Mimikry eines metastasierenden Lungenkarzinoms
24. Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”
25. 1096O Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study
26. Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-Small Cell Lung Cancer who Received Prior Immunotherapy
27. Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
28. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
29. 1405P Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
30. 1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
31. 1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
32. CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC
33. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
34. Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study
35. FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
36. OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC
37. PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results
38. OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC
39. MO01.21 Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-Small Cell Lung Cancer who Received Prior Immunotherapy
40. Malignant thymoma: current status of classification and multimodality treatment
41. 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
42. 1246P Hybrid capture-based assays in primary diagnostics of NSCLC patients: Results from the NEOlung study
43. 1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study
44. LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
45. Canopy-1: Phase 3 Study of Canakinumab/Placebo + Pembrolizumab + Platinum-chemotherapy in Untreated Stage III b-IV NSCLC pts
46. Pulmonary 15NO uptake in interstitial lung disease
47. 1143P Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy
48. 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort
49. POSEIDON : A phase 3 study of first-line Durvalumab +/- Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC
50. Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.